![]() | |
![]() Headquarters in Mainz | |
Company type | Public |
---|---|
Nasdaq: BNTX | |
ISIN | US09075V1026 |
Industry | Biotechnology |
Founded | 2008 |
Founders |
|
Headquarters | , Germany |
Number of locations | 17 (2024[1]) |
Area served | Worldwide |
Key people |
|
Products | Pfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates |
Services | Immunotherapy |
Revenue | ![]() |
![]() | |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | ![]() |
Website | biontech |
Footnotes / references BioNTech FY 2024 report[2] |
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology[4][5] testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.[6][7]